Recent Updates
Recently added Catalysts
REGN

Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization

Friday, October 30, 2015 1 min read
Key Takeaway: Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization

Full Press Release Details

Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization.
Tags: REGN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 30, 2015